Resmed (RMD) Cash from Financing Activities (2009 - 2026)

Resmed (RMD) has 18 years of Cash from Financing Activities data on file, last reported at -$255.2 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 77.16% year-over-year to -$255.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$907.8 million (down 8.63% YoY) and the FY2025 annual result came in at -$606.3 million, up 45.84% from the prior year.
• Cash from Financing Activities advanced to -$255.2 million in Q1 2026, from -$258.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $932.9 million in Q4 2022 to a low of -$393.3 million in Q2 2024.
• A 5-year average of -$120.6 million and a median of -$163.9 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 527.99% — and 2023, when it slumped 427.99%.
• Tracing RMD's Cash from Financing Activities over 5 years: stood at $932.9 million in 2022, then sank by 125.61% to -$239.0 million in 2023, then jumped by 38.26% to -$147.5 million in 2024, then sank by 75.11% to -$258.3 million in 2025, then grew by 1.2% to -$255.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$255.2 million (Q1 2026), -$258.3 million (Q4 2025), and -$230.3 million (Q3 2025), per Business Quant data.